NEXT Oncology

Iambic Therapeutics has completed dose escalation for IAM1363, an AI-designed small molecule inhibitor targeting wild-type and oncogenic mutant HER2 proteins.

Biohaven's Trop2-directed ADC BHV-1510 demonstrated tumor reduction in all six patients when combined with cemiplimab, including confirmed partial responses and activity in brain metastases.

Tagworks Pharmaceuticals received FDA clearance for its investigational new drug application of TGW101, a first-in-class antibody-drug conjugate targeting TAG-72 in advanced solid tumors.

Alterome Therapeutics has dosed the first patient in a Phase 1/1b trial of ALTA3263, a novel oral pan-KRAS inhibitor designed to target over 90% of KRAS mutations in advanced solid tumors.